Literature DB >> 199052

Lymphocytic infiltration in long-survival glioblastomas: possible host's resistance.

N Di Lorenzo, L Palma, S Nicole.   

Abstract

A series of 200 patients operated on at the Rome University Neurosurgical Clinic for primary glioblastoma is analyzed. Eight of these patients (4%) survived for over four years. The histological preparations showed more or less heavy perivascular lymphocytic infiltration in six of these cases. Since such infiltrations in malignant tumours of other organs are recognized as having an immune function, expressing the host's resistance to his tumour, the longer survival of the cases considered may well denote an immune defensive mechanism.

Entities:  

Mesh:

Year:  1977        PMID: 199052     DOI: 10.1007/bf01405238

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  27 in total

1.  IS THE BRAIN "AN IMMUNOLOGICALLY PRIVILEGED SITE"?I. STUDIES BASED ON INTRACEREBRAL TUMOR HOMOTRANSPLANTATION AND ISOTRANSPLANTATION TO SENSITIZED HOSTS.

Authors:  L C SCHEINBERG; F L EDELMAN; W A LEVY
Journal:  Arch Neurol       Date:  1964-09

2.  Glioblastoma multiforme: a clinical survey.

Authors:  J G ROTH; A R ELVIDGE
Journal:  J Neurosurg       Date:  1960-07       Impact factor: 5.115

3.  Cell-bound antiglial immunity in patients with malignant tumors of the brain.

Authors:  T Wahlström; E Saksela; H Troupp
Journal:  Cell Immunol       Date:  1973-02       Impact factor: 4.868

4.  Demonstration of cell-mediated immunity to human neoplasms of various histological types.

Authors:  I Hellström; K E Hellström; H O Sjögren; G A Warner
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

5.  Glioblastoma multiforme: its treatment and some factors effecting survival.

Authors:  R Jelsma; P C Bucy
Journal:  Arch Neurol       Date:  1969-02

6.  The treatment of glioblastoma multiforme of the brain.

Authors:  R Jelsma; P C Bucy
Journal:  J Neurosurg       Date:  1967-11       Impact factor: 5.115

7.  Evidence for tumor-specific immune response in patients with primary brain tumors.

Authors:  W H Brooks; D A Horwitz; M G Netsky
Journal:  Surg Forum       Date:  1972

8.  [On the question of longer survival time in glioblastomas].

Authors:  F Gullotta; W Bettag
Journal:  Acta Neurochir (Wien)       Date:  1967       Impact factor: 2.216

9.  Possible host resistance in carcinoma of the breast: a histological study.

Authors:  I M Hamlin
Journal:  Br J Cancer       Date:  1968-09       Impact factor: 7.640

10.  [Frequency and significance of lymphoplasmocyte infiltration in human gliomas (author's transl)].

Authors:  D Schiffer; G Croveri; C Pautasso
Journal:  Tumori       Date:  1974 May-Jun
View more
  11 in total

1.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.

Authors:  N G Baldwin; C D Rice; T M Tuttle; H D Bear; J I Hirsch; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

Review 2.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

3.  Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation.

Authors:  T Morimura; C Neuchrist; K Kitz; H Budka; O Scheiner; D Kraft; H Lassmann
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 4.  Immunobiologic aspects of the brain and human gliomas. A review.

Authors:  C J Wikstrand; D D Bigner
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

5.  Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma.

Authors:  J Vaquero; R Martínez; S Oya; S Coca; L Barbolla; J Ramiro; F G Salazar
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

6.  Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes.

Authors:  Christopher L Mariani; Joshua G Kouri; Wolfgang J Streit
Journal:  J Neurooncol       Date:  2006-04-13       Impact factor: 4.130

7.  Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme. A phase 1 (toxicity) study.

Authors:  P Steinbok; J P Thomas; L Grossman; C L Dolman
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

8.  Intrathecal injection of autologous leucocytes in glioblastoma: circulatory dynamics within the subarachnoid space and clinical results.

Authors:  J Vaquero; R Martínez; L Barbolla; J de Haro; S de Oya; S Coca; J Ramiro
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

9.  The utilization of native glioma antigens in the assessment of cellular and humoral immune responses in malignant glioma patients.

Authors:  M L Apuzzo; K M Sheikh; M H Weiss; J S Heiden; T Kurze
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

10.  A very rare case report of long-term survival: A patient operated on in 1994 of glioblastoma multiforme and currently in perfect health.

Authors:  Riccardo Caruso; Alessandro Pesce; Venceslao Wierzbicki
Journal:  Int J Surg Case Rep       Date:  2017-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.